Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 31, 2026, 1:47 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 217–240 of 10,545 matching trials from the live ClinicalTrials.gov search.
Filters: Cincinnati, Ohio Clear all
Recruiting No phase listed Observational

A Study for Participants Previously Treated With Century Therapeutics Cellular Therapy Product

NCT05768269
View directory record Official record
Conditions
Hematological Malignancy, Solid Tumor Malignancy
Interventions
No Intervention
Other
Lead sponsor
Century Therapeutics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
375 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2040
U.S. locations
7
States / cities
Gilbert, Arizona • Los Angeles, California • Baltimore, Maryland + 4 more
Source: ClinicalTrials.gov public record
Updated Jun 25, 2025 · Synced Oct 31, 2026, 1:47 AM EDT
Completed No phase listed Observational

Study to Evaluate Blood Cell Lines From Patients With Gaucher Disease

NCT00351156
View directory record Official record
Conditions
Gaucher Disease
Interventions
Blood sample
Procedure
Lead sponsor
Amicus Therapeutics
Industry
Eligibility
Not listed
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2007
U.S. locations
7
States / cities
San Francisco, California • Coral Springs, Florida • Decatur, Georgia + 4 more
Source: ClinicalTrials.gov public record
Updated Aug 19, 2010 · Synced Oct 31, 2026, 1:47 AM EDT
Not listed Phase 2 Interventional

A Study of Oral BTD-001 in Adults With Idiopathic Hypersomnia

NCT03542851
View directory record Official record
Conditions
Idiopathic Hypersomnia
Interventions
Pentetrazol (PTZ), Placebo oral capsule
Drug
Lead sponsor
Balance Therapeutics
Industry
Eligibility
18 Years to 70 Years
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
32
States / cities
Birmingham, Alabama • Scottsdale, Arizona • Orange, California + 28 more
Source: ClinicalTrials.gov public record
Updated Apr 29, 2020 · Synced Oct 31, 2026, 1:47 AM EDT
Completed Phase 3 Interventional Results available

Evaluating the Effects of Tradipitant vs. Placebo in Atopic Dermatitis (EPIONE)

NCT03568331
View directory record Official record
Conditions
Atopic Dermatitis
Interventions
Tradipitant, Placebo
Drug
Lead sponsor
Vanda Pharmaceuticals
Industry
Eligibility
18 Years to 70 Years
Enrollment
375 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
70
States / cities
Birmingham, Alabama • Tempe, Arizona • Encino, California + 60 more
Source: ClinicalTrials.gov public record
Updated May 13, 2024 · Synced Oct 31, 2026, 1:47 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study of Single and Repeated Doses of LY3556050 in Healthy Participants

NCT05341102
View directory record Official record
Conditions
Healthy
Interventions
LY3556050, Placebo
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years to 80 Years
Enrollment
106 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2017
U.S. locations
1
States / cities
Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Apr 22, 2022 · Synced Oct 31, 2026, 1:47 AM EDT
Completed Phase 3 Interventional Accepts healthy volunteers

A Study to Evaluate the Efficacy of an RSV F Vaccine in Older Adults

NCT02608502
View directory record Official record
Conditions
Respiratory Syncytial Virus (RSV)
Interventions
RSV-F Vaccine, Phosphate Buffer Placebo
Biological
Lead sponsor
Novavax
Industry
Eligibility
60 Years and older
Enrollment
11,850 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2016
U.S. locations
60
States / cities
Birmingham, Alabama • Mobile, Alabama • Mesa, Arizona + 51 more
Source: ClinicalTrials.gov public record
Updated Jul 19, 2022 · Synced Oct 31, 2026, 1:47 AM EDT
Completed Phase 2 Interventional Results available

Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study In Subjects With Osteoarthritic Pain Of The Knee

NCT00689273
View directory record Official record
Conditions
Osteoarthritis, Knee
Interventions
PF-04136309, Placebo
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 75 Years
Enrollment
159 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008
U.S. locations
18
States / cities
DeLand, Florida • South Miami, Florida • Overland Park, Kansas + 10 more
Source: ClinicalTrials.gov public record
Updated Jul 13, 2021 · Synced Oct 31, 2026, 1:47 AM EDT
Completed Phase 2 Interventional Results available

A Study of Rodatristat Ethyl in Patients With Pulmonary Arterial Hypertension (Core OLE)

NCT04712669
View directory record Official record
Conditions
Pulmonary Arterial Hypertension
Interventions
rodatristat ethyl 300 mg tablet BID, rodatristat ethyl 600 mg BID, Placebo
Drug
Lead sponsor
Altavant Sciences GmbH
Industry
Eligibility
18 Years and older
Enrollment
108 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
28
States / cities
Phoenix, Arizona • La Jolla, California • Los Angeles, California + 23 more
Source: ClinicalTrials.gov public record
Updated Jun 4, 2025 · Synced Oct 31, 2026, 1:47 AM EDT
Completed Phase 2 Interventional Results available

Brain Irradiation in Treating Patients With Limited-Stage Small Cell Lung Cancer

NCT00057746
View directory record Official record
Conditions
Lung Cancer
Interventions
Prophylactic cranial irradiation, 2.5 Gy fx, Prophylactic cranial irradiation, 2.0 Gy fx, Prophylactic cranial irradiation, 1.5 Gy fx
Radiation
Lead sponsor
Radiation Therapy Oncology Group
Network
Eligibility
Up to 120 Years
Enrollment
265 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2013
U.S. locations
217
States / cities
Birmingham, Alabama • Phoenix, Arizona • Scottsdale, Arizona + 160 more
Source: ClinicalTrials.gov public record
Updated May 25, 2016 · Synced Oct 31, 2026, 1:47 AM EDT
Completed Phase 3 Interventional

Use of a Dual-agent Local Analgesic (Bupivacaine-meloxicam) for Abdominal Incisions in Patients Undergoing Retropubic Mid-urethral Sling Surgery

NCT05702827
View directory record Official record
Conditions
Stress Urinary Incontinence, Surgical Incision, Pain Vulva
Interventions
Bupivacaine-Meloxicam
Drug
Lead sponsor
TriHealth Inc.
Other
Eligibility
18 Years and older · Female only
Enrollment
148 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
2
States / cities
Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Nov 22, 2024 · Synced Oct 31, 2026, 1:47 AM EDT
Terminated No phase listed Observational Results available

Safety and Performance Study of the Siello S Pacing Lead

NCT01791127
View directory record Official record
Conditions
Safety and Effectiveness of the Siello S Lead
Interventions
market-released BIOTRONIK pacemaker system including one or two Siello S leads.
Device
Lead sponsor
Biotronik, Inc.
Industry
Eligibility
18 Years and older
Enrollment
1,758 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2019
U.S. locations
53
States / cities
La Jolla, California • La Mesa, California • New Haven, Connecticut + 50 more
Source: ClinicalTrials.gov public record
Updated Jun 1, 2020 · Synced Oct 31, 2026, 1:47 AM EDT
Completed Phase 2 Interventional

SB-773812 Administered In Adults With Schizophrenia

NCT00259870
View directory record Official record
Conditions
Schizophrenia
Interventions
SB-773812, Olanzapine
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years to 65 Years
Enrollment
338 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2007
U.S. locations
18
States / cities
Birmingham, Alabama • Cerritos, California • Garden Grove, California + 15 more
Source: ClinicalTrials.gov public record
Updated Mar 23, 2017 · Synced Oct 31, 2026, 1:47 AM EDT
Completed Phase 2Phase 3 Interventional

Safety and Efficacy Study of SYN115 in Parkinson's Patients Using Levodopa to Treat End of Dose Wearing Off

NCT01283594
View directory record Official record
Conditions
Parkinson's Disease
Interventions
Tozadenant (SYN115) 60 mg BID, Placebo, Levodopa (L-dopa), Tozadenant (SYN115) 120 mg BID, Tozadenant (SYN115) 180 mg BID, Tozadenant (SYN115) 240 mg BID
Drug
Lead sponsor
Biotie Therapies Inc.
Industry
Eligibility
30 Years to 80 Years
Enrollment
420 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
40
States / cities
Birmingham, Alabama • La Jolla, California • Loma Linda, California + 37 more
Source: ClinicalTrials.gov public record
Updated Jan 17, 2019 · Synced Oct 31, 2026, 1:47 AM EDT
Active, not recruiting No phase listed Observational

NCI COVID-19 in Cancer Patients, NCCAPS Study

NCT04387656
View directory record Official record
Conditions
COVID-19 Infection, Hematopoietic and Lymphatic System Neoplasm, Malignant Solid Neoplasm, Metastatic Malignant Solid Neoplasm
Interventions
Biospecimen Collection, Data Collection, Quality-of-Life Assessment, Questionnaire Administration
Procedure · Other
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
Not listed
Enrollment
1,877 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2027
U.S. locations
928
States / cities
Birmingham, Alabama • Mobile, Alabama • Anchorage, Alaska + 589 more
Source: ClinicalTrials.gov public record
Updated Oct 26, 2026 · Synced Oct 31, 2026, 1:47 AM EDT
Completed Phase 2 Interventional Results available

Vinflunine in Hormone Refractory Prostate Cancer (HRPC)

NCT00545766
View directory record Official record
Conditions
Prostate Cancer
Interventions
Vinflunine
Drug
Lead sponsor
SCRI Development Innovations, LLC
Other
Eligibility
18 Years and older · Male only
Enrollment
41 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
12
States / cities
Fort Myers, Florida • Jacksonville, Florida • Orlando, Florida + 8 more
Source: ClinicalTrials.gov public record
Updated Dec 16, 2021 · Synced Oct 31, 2026, 1:47 AM EDT
Terminated Phase 1 Interventional Accepts healthy volunteers

Two Anesthetic Techniques in Magnetic Resonance Imaging (MRI)

NCT00894751
View directory record Official record
Conditions
Magnetic Resonance Imaging, Anesthesia
Interventions
dexmedetomidine, propofol
Drug
Lead sponsor
Children's Hospital Medical Center, Cincinnati
Other
Eligibility
12 Months to 7 Years
Enrollment
98 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2011
U.S. locations
1
States / cities
Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Sep 21, 2020 · Synced Oct 31, 2026, 1:47 AM EDT
Completed Phase 2 Interventional Accepts healthy volunteers

Eldery High Dose TIV 2005

NCT00115531
View directory record Official record
Conditions
Influenza
Interventions
Trivalent inactivated influenza vaccine
Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
65 Years and older
Enrollment
414 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2005
U.S. locations
5
States / cities
Iowa City, Iowa • Baltimore, Maryland • St Louis, Missouri + 2 more
Source: ClinicalTrials.gov public record
Updated Dec 19, 2014 · Synced Oct 31, 2026, 1:47 AM EDT
Completed Phase 2 Interventional Results available

S0601 Rituximab, Combination Chemotherapy, and Bortezomib Followed by Bortezomib Alone in Treating Patients With Newly Diagnosed Mantle Cell Lymphoma

NCT00376961
View directory record Official record
Conditions
Lymphoma
Interventions
rituximab, bortezomib, cyclophosphamide, doxorubicin hydrochloride, prednisone, vincristine sulfate
Biological · Drug
Lead sponsor
SWOG Cancer Research Network
Network
Eligibility
18 Years to 120 Years
Enrollment
68 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2017
U.S. locations
147
States / cities
Anchorage, Alaska • Tucson, Arizona • Little Rock, Arkansas + 95 more
Source: ClinicalTrials.gov public record
Updated Nov 6, 2017 · Synced Oct 31, 2026, 1:47 AM EDT
Recruiting Not applicable Interventional Accepts healthy volunteers

Quantifying Motor Network Dynamics to Predict and Enhance Outcomes in Pediatric Dystonia

NCT07325175
View directory record Official record
Conditions
Dystonia, Pediatric, Deep Brain Stimulation, Motor Development
Interventions
DBS
Device
Lead sponsor
Children's Hospital Medical Center, Cincinnati
Other
Eligibility
6 Years to 21 Years
Enrollment
75 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026 – 2031
U.S. locations
1
States / cities
Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Oct 20, 2026 · Synced Oct 31, 2026, 1:47 AM EDT
Completed Phase 3 Interventional Results available

Study HZA106829: Efficacy/Safety Study of Fluticasone Furoate/Vilanterol (GW642444) in Adult and Adolescent Asthmatics

NCT01134042
View directory record Official record
Conditions
Asthma
Interventions
Fluticasone Furoate/Vilanterol Inhalation Powder, Fluticasone Furoate Inhalation Powder, Fluticasone Propionate Inhalation Powder, Placebo Inhalation Powder 1, Placebo Inhalation Powder 2
Drug · Other
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
12 Years and older
Enrollment
587 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
23
States / cities
Bell Gardens, California • Huntington Beach, California • Long Beach, California + 19 more
Source: ClinicalTrials.gov public record
Updated Jan 11, 2017 · Synced Oct 31, 2026, 1:47 AM EDT
Completed Phase 2 Interventional Results available

Efficacy, Safety, and Tolerability of Selonsertib (GS-4997) in Participants With Diabetic Kidney Disease

NCT02177786
View directory record Official record
Conditions
Diabetic Kidney Disease
Interventions
Selonsertib, Placebo to match selonsertib
Drug
Lead sponsor
Gilead Sciences
Industry
Eligibility
18 Years to 75 Years
Enrollment
334 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
100
States / cities
Birmingham, Alabama • Huntsville, Alabama • Toney, Alabama + 81 more
Source: ClinicalTrials.gov public record
Updated Nov 5, 2019 · Synced Oct 31, 2026, 1:47 AM EDT
Completed Phase 3 Interventional Results available

Open-label, Single Arm Trial of BI 695502 in Patients With Previously Untreated Metastatic Colorectal Cancer

NCT02776683
View directory record Official record
Conditions
Colorectal Neoplasms
Interventions
BI 695502, Avastin
Drug
Lead sponsor
Boehringer Ingelheim
Industry
Eligibility
18 Years and older
Enrollment
123 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
25
States / cities
Phoenix, Arizona • Anaheim, California • Denver, Colorado + 19 more
Source: ClinicalTrials.gov public record
Updated Nov 21, 2019 · Synced Oct 31, 2026, 1:47 AM EDT
Completed Phase 3 Interventional Results available

Idalopirdine in Patients With Mild-moderate Alzheimer's Disease Treated With Donepezil

NCT02006641
View directory record Official record
Conditions
Alzheimer's Disease
Interventions
Placebo, Idalopirdine
Drug
Lead sponsor
H. Lundbeck A/S
Industry
Eligibility
50 Years and older
Enrollment
858 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
48
States / cities
Phoenix, Arizona • Fayetteville, Arkansas • Anaheim, California + 43 more
Source: ClinicalTrials.gov public record
Updated Feb 20, 2018 · Synced Oct 31, 2026, 1:47 AM EDT
Completed Phase 3 Interventional

A Study To Evaluate The Efficacy And Safety Of A Once-Daily Investigational Nasal Spray In Adults And Adolescents With Perennial Allergic Rhinitis (PAR).

NCT00103454
View directory record Official record
Conditions
Rhinitis, Allergic, Perennial
Interventions
GW685698X
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
12 Years and older
Enrollment
288 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005
U.S. locations
43
States / cities
Little Rock, Arkansas • Los Angeles, California • Mission Viejo, California + 37 more
Source: ClinicalTrials.gov public record
Updated Sep 19, 2016 · Synced Oct 31, 2026, 1:47 AM EDT